Pain is a subjective experience with affective and cognitive components, an """"""""unpleasant sensory and emotional experience associated with actual or potential tissue damage that serves an essential role in alerting an individual to potentially harmful stimuli in the environment"""""""". But chronic pain, often disabling and refractory to treatment, represents a difficult medical problem with enormous societal impact. Herpes simplex virus (HSV) naturally targets with high efficiency to neurons of the dorsal root ganglion (DRG) from peripheral inoculation. We have demonstrated that HSV based vectors can be used to transduce neurons of the DRG to achieve an antinociceptive effect in models of inflammatory pain, neuropathic pain, and pain resulting from tumor in bone. The effect is local, synergistic with morphine, and persists despite tolerance to morphine. The preclinical data for this novel approach to the treatment of pain is compelling. In response to the RFA, we propose a series of studies to investigate the hypothesis that HSV-mediated gene transfer to the DRG may be used to treat chronic pain. These studies are designed to overcome the barriers that stand between preclinical proof-of-principle experiments and the development of a treatment for the human disease, and to create novel vectors to enhance gene therapy for specific types of pain.
Five specific aims are outlined.
Specific Aim 1. To define the duration and dose-response characteristics of the vector-mediated analgesic effect.
Specific Aim 2. To construct a vector with a regulatable """"""""switch"""""""" to control vector-mediated enkephalin expression in vivo.
Specific Aim 3. To test the effect of prior immunity on vector transduction, the potential of the recombinant vector to reactivate latent virus, and to study the level and kinetics of the anti-nociceptive response following repeated vector re-inoculation.
Specific Aim 4. To systematically evaluate biodistribution and biosafety of the recombinant enkephalin expressing vector in rodents.
Specific Aim 5. To create and test novel HSV-based vectors in models of neuropathic, inflammatory, and cancer pain.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS044507-01
Application #
6546992
Study Section
Special Emphasis Panel (ZNS1-SRB-S (01))
Program Officer
Porter, Linda L
Project Start
2002-09-30
Project End
2006-08-31
Budget Start
2002-09-30
Budget End
2003-08-31
Support Year
1
Fiscal Year
2002
Total Cost
$419,898
Indirect Cost
Name
University of Pittsburgh
Department
Neurology
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Wu, Zetang; Wang, Shiyong; Gruber, Sandy et al. (2013) Full-length membrane-bound tumor necrosis factor-? acts through tumor necrosis factor receptor 2 to modify phenotype of sensory neurons. Pain 154:1778-82
Sun, J; Liu, S; Mata, M et al. (2012) Transgene-mediated expression of tumor necrosis factor soluble receptor attenuates morphine tolerance in rats. Gene Ther 19:101-8
Wolfe, Darren; Mata, Marina; Fink, David J (2012) Targeted drug delivery to the peripheral nervous system using gene therapy. Neurosci Lett 527:85-9
Zhou, Zhigang; Kim, Jeeyong; Insolera, Ryan et al. (2011) Rho GTPase regulation of ýý-synuclein and VMAT2: implications for pathogenesis of Parkinson's disease. Mol Cell Neurosci 48:29-37
Fink, David J; Wechuck, James; Mata, Marina et al. (2011) Gene therapy for pain: results of a phase I clinical trial. Ann Neurol 70:207-12
Wolfe, D; Mata, M; Fink, D J (2009) A human trial of HSV-mediated gene transfer for the treatment of chronic pain. Gene Ther 16:455-60
Glorioso, J C; Fink, D J (2009) Gene therapy for pain: introduction to the special issue. Gene Ther 16:453-4
Chattopadhyay, Munmun; Mata, Marina; Fink, David J (2008) Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy. J Neurosci 28:6652-8
Peng, Xiang-min; Zhou, Zhi-gang; Glorioso, Joseph C et al. (2006) Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury. Ann Neurol 59:843-51
Chattopadhyay, M; Krisky, D; Wolfe, D et al. (2005) HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther 12:1377-84

Showing the most recent 10 out of 12 publications